These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Selective blockade of leukotriene production by a single dose of the FPL 64170XX 0.5% enema in active ulcerative colitis. Kjeldsen J, Laursen LS, Hillingsø J, Mertz-Nielsen A, Bukhave K, Rask-Madsen J, Lauritsen K. Pharmacol Toxicol; 1995 Dec; 77(6):371-6. PubMed ID: 8835361 [Abstract] [Full Text] [Related]
4. The in vitro 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skin. Barr RM, Black AK, Dowd PM, Koro O, Mistry K, Isaacs JL, Greaves MW. Br J Clin Pharmacol; 1988 Jan; 25(1):23-6. PubMed ID: 2835975 [Abstract] [Full Text] [Related]
5. Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Collawn C, Rubin P, Perez N, Bobadilla J, Cabrera G, Reyes E, Borovoy J, Kershenobich D. Am J Gastroenterol; 1992 Mar; 87(3):342-6. PubMed ID: 1539569 [Abstract] [Full Text] [Related]
6. 2-substituted indazolinones: orally active and selective 5-lipoxygenase inhibitors with anti-inflammatory activity. Foster SJ, Bruneau P, Walker ER, McMillan RM. Br J Pharmacol; 1990 Jan; 99(1):113-8. PubMed ID: 2110012 [Abstract] [Full Text] [Related]
8. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Gastroenterology; 1986 Oct; 91(4):837-44. PubMed ID: 3017804 [Abstract] [Full Text] [Related]
9. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Tateson JE, Randall RW, Reynolds CH, Jackson WP, Bhattacherjee P, Salmon JA, Garland LG. Br J Pharmacol; 1988 Jun; 94(2):528-39. PubMed ID: 2840160 [Abstract] [Full Text] [Related]
10. Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C. Hawthorne AB, Boughton-Smith NK, Whittle BJ, Hawkey CJ. Gut; 1992 Apr; 33(4):513-7. PubMed ID: 1316305 [Abstract] [Full Text] [Related]
18. Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis. Bertrán X, Mañé J, Fernández-Bañares F, Castellá E, Bartolí R, Ojanguren I, Esteve M, Gassull MA. Gut; 1996 Jun; 38(6):899-904. PubMed ID: 8984030 [Abstract] [Full Text] [Related]
19. The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats. Zarif A, Eiznhamer D, Callaghan C, Doria MI, Broutman L, Keshavarzian A. Inflammation; 1996 Jun; 20(3):217-27. PubMed ID: 8796377 [Abstract] [Full Text] [Related]